April 25, 2024
Market Now
Biogenetics inks US$7m cancer drug license deal
[DISCLOSURE] Biogenetics (044480) announced on Feb. 27 that it has signed a US$7 million licensing deal with Singapore’s ASLAN Pharmaceuticals to introduce anti-cancer drug Varlitinib in Korea.
It has secured an exclusive right to commercialize the medicine, world's first drug that targets bile duct cancer, and the contract is valid for 10 years from the first day it begins selling in Korea.
By Hwang You-mee (glamazon@heraldcorp.com)
It has secured an exclusive right to commercialize the medicine, world's first drug that targets bile duct cancer, and the contract is valid for 10 years from the first day it begins selling in Korea.
By Hwang You-mee (glamazon@heraldcorp.com)
![[KH Explains] Korean shipbuilding stocks rally: Real growth or bubble?](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=151&simg=/content/image/2024/04/25/20240425050656_0.jpg)
![[Hello India] Hyundai Motor vows to boost 'clean mobility' in India](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=151&simg=/content/image/2024/04/25/20240425050672_0.jpg)
